The Kano State Drugs and Medical Consumables Supply Agency (DMCSA) has recorded significant financial and operational improvements, settling over 95 percent of inherited debts while strengthening drug availability across public health facilities in the state.
The Director General of the agency, Pharm. Gali Sule disclosed this after the agency’s ninth quarterly review meeting held in January 2026 to assess activities carried out between October and December 2025.
According to him, the quarterly review meetings serve as a platform to evaluate key performance indicators, challenges and progress made by the agency.
He explained that among the major indicators regularly assessed are the availability of drugs across health facilities and the overall financial standing of the agency.
Gali recalled that the administration inherited a negative fund value of N102 million upon assumption of office in 2023. He noted that through prudent management and strategic reforms, the agency’s financial position improved steadily over time.
He revealed that the agency’s fund value rose from N377 million recorded during the September 2025 quarterly review meeting to N532 million as of December 2025, describing it as the highest increase recorded since the commencement of the review process.
The agency also reviewed the status of liabilities inherited from the previous administration, which stood at N1.178 million (one billion, one hundred and seventy-eight million naira).
According to him, only N46 million remains unpaid as of December 2025, indicating that more than 95 percent of the debt burden has been cleared.
He expressed optimism that the remaining debt would be fully settled before the end of the first quarter of 2026.
Speaking further, the Director General said one of the major objectives of establishing the agency was to ensure the supply of quality and affordable drugs to residents of Kano State.
He however admitted that limited fund value had affected the agency’s ability to procure drugs and medical consumables at the most competitive prices.
Sule explained that while suppliers are expected to be paid within three to four months, the agency currently settles payments between five and seven months due to financial constraints, a situation he said affects affordability.
The Director General, however, assured residents that the government is exploring the possibility of securing a credible loan facility in 2026 to boost the agency’s fund value and improve procurement capacity.
He added that the move would enable the agency to source drugs at cheaper rates and ultimately guarantee improved affordability and availability of medicines across public health facilities in Kano State.